VolitionRx recently had data published in the peer-reviewed journal Clinical Epigenetics, which confirmed the utility of the NuQ platform for detecting pancreatic cancer. Also, combining NuQ assays with the CA 19-9 biomarker, it was able to achieve 92% sensitivity and 90% specificity. Additionally, the company announced interim data from a 4,800-subject trial in colorectal cancer (CRC) and received its first CE mark in Europe for an assay for the detection of CRC.
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
New pancreatic data and a CE mark
VolitionRx recently had data published in the peer-reviewed journal Clinical Epigenetics, which confirmed the utility of the NuQ platform for detecting pancreatic cancer. Also, combining NuQ assays with the CA 19-9 biomarker, it was able to achieve 92% sensitivity and 90% specificity. Additionally, the company announced interim data from a 4,800-subject trial in colorectal cancer (CRC) and received its first CE mark in Europe for an assay for the detection of CRC.